PL3173400T3 - Leki zawierające modyfikacje krystaliczne (1R, 2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu - Google Patents
Leki zawierające modyfikacje krystaliczne (1R, 2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenoluInfo
- Publication number
- PL3173400T3 PL3173400T3 PL16203848T PL16203848T PL3173400T3 PL 3173400 T3 PL3173400 T3 PL 3173400T3 PL 16203848 T PL16203848 T PL 16203848T PL 16203848 T PL16203848 T PL 16203848T PL 3173400 T3 PL3173400 T3 PL 3173400T3
- Authority
- PL
- Poland
- Prior art keywords
- dimethylamino
- phenol
- propyl
- ethyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
- C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07023728 | 2007-12-07 | ||
| EP08857298.7A EP2240431B1 (de) | 2007-12-07 | 2008-12-05 | Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| PCT/EP2008/010330 WO2009071310A1 (de) | 2007-12-07 | 2008-12-05 | Kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| EP16203848.3A EP3173400B1 (de) | 2007-12-07 | 2008-12-05 | Arzneimittel enthaltend kristalline modifikationen von (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3173400T3 true PL3173400T3 (pl) | 2020-05-18 |
Family
ID=39272207
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08857298T PL2240431T3 (pl) | 2007-12-07 | 2008-12-05 | Krystaliczne modyfikacje (1R,2R)-3-(3-dimetyloamino-1-etylo-2-metyIopropylo)fenoIu |
| PL16203848T PL3173400T3 (pl) | 2007-12-07 | 2008-12-05 | Leki zawierające modyfikacje krystaliczne (1R, 2R)-3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenolu |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08857298T PL2240431T3 (pl) | 2007-12-07 | 2008-12-05 | Krystaliczne modyfikacje (1R,2R)-3-(3-dimetyloamino-1-etylo-2-metyIopropylo)fenoIu |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8134032B2 (pl) |
| EP (2) | EP2240431B1 (pl) |
| CN (3) | CN101939287B (pl) |
| CY (2) | CY1118976T1 (pl) |
| DK (2) | DK3173400T3 (pl) |
| ES (2) | ES2764451T3 (pl) |
| HR (2) | HRP20170481T1 (pl) |
| HU (2) | HUE047275T2 (pl) |
| IL (2) | IL206197A (pl) |
| LT (1) | LT2240431T (pl) |
| PL (2) | PL2240431T3 (pl) |
| PT (2) | PT3173400T (pl) |
| SI (2) | SI2240431T1 (pl) |
| WO (1) | WO2009071310A1 (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100272815A1 (en) * | 2009-04-28 | 2010-10-28 | Actavis Group Ptc Ehf | Amorphous form of tapentadol hydrochloride |
| US8288592B2 (en) | 2009-09-22 | 2012-10-16 | Actavis Group Ptc Ehf | Solid state forms of tapentadol salts |
| EP2566461A2 (de) | 2010-05-05 | 2013-03-13 | Ratiopharm GmbH | Festes tapentadol in nicht-kristalliner form |
| WO2012051246A1 (en) | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
| WO2013111161A2 (en) * | 2012-01-10 | 2013-08-01 | Msn Laboratories Limited | Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof |
| WO2014023652A1 (en) * | 2012-08-06 | 2014-02-13 | Ratiopharm Gmbh | Pharmaceutical formulation comprising tapentadol and cyclodextrin |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| CZ307492B6 (cs) | 2014-02-04 | 2018-10-17 | Zentiva, K.S. | Pevná forma maleátu tapentadolu a způsob její přípravy |
| GB2523089A (en) * | 2014-02-12 | 2015-08-19 | Azad Pharmaceutical Ingredients Ag | Stable polymorph form B of tapentadol hydrochloride |
| ES2966219T3 (es) | 2016-04-19 | 2024-04-19 | Ratiopharm Gmbh | Fosfato de tapentadol amorfo |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1027666C (zh) * | 1993-02-20 | 1995-02-15 | 袁晓辉 | 高分子聚合物正温度系数热敏电阻材料 |
| DE4426245A1 (de) * | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| DE10326097A1 (de) * | 2003-06-06 | 2005-01-05 | Grünenthal GmbH | Verfahren zur Herstellung von Dimethyl-(3-aryl-butyl)-aminverbindungen |
| ATE368639T1 (de) * | 2004-06-28 | 2007-08-15 | Gruenenthal Gmbh | Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid |
| DE102005034974A1 (de) * | 2005-07-22 | 2007-04-19 | Grünenthal GmbH | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
| US20070254960A1 (en) * | 2006-04-28 | 2007-11-01 | Gruenenthal Gmbh | Pharmaceutical combination |
-
2008
- 2008-12-05 HU HUE16203848A patent/HUE047275T2/hu unknown
- 2008-12-05 DK DK16203848T patent/DK3173400T3/da active
- 2008-12-05 US US12/329,111 patent/US8134032B2/en active Active
- 2008-12-05 ES ES16203848T patent/ES2764451T3/es active Active
- 2008-12-05 DK DK08857298.7T patent/DK2240431T3/en active
- 2008-12-05 SI SI200831791A patent/SI2240431T1/sl unknown
- 2008-12-05 LT LTEP08857298.7T patent/LT2240431T/lt unknown
- 2008-12-05 PT PT162038483T patent/PT3173400T/pt unknown
- 2008-12-05 ES ES08857298.7T patent/ES2623413T3/es active Active
- 2008-12-05 EP EP08857298.7A patent/EP2240431B1/de active Active
- 2008-12-05 PT PT88572987T patent/PT2240431T/pt unknown
- 2008-12-05 PL PL08857298T patent/PL2240431T3/pl unknown
- 2008-12-05 PL PL16203848T patent/PL3173400T3/pl unknown
- 2008-12-05 CN CN200880126383.XA patent/CN101939287B/zh active Active
- 2008-12-05 WO PCT/EP2008/010330 patent/WO2009071310A1/de active Application Filing
- 2008-12-05 HU HUE08857298A patent/HUE031126T2/en unknown
- 2008-12-05 SI SI200832101T patent/SI3173400T1/sl unknown
- 2008-12-05 EP EP16203848.3A patent/EP3173400B1/de active Active
- 2008-12-05 CN CN201410468681.4A patent/CN104447361B/zh active Active
- 2008-12-05 CN CN201410468436.3A patent/CN104447360B/zh active Active
-
2010
- 2010-06-06 IL IL206197A patent/IL206197A/en active IP Right Grant
-
2015
- 2015-03-01 IL IL237478A patent/IL237478A0/en unknown
-
2017
- 2017-03-21 HR HRP20170481TT patent/HRP20170481T1/hr unknown
- 2017-04-07 CY CY20171100414T patent/CY1118976T1/el unknown
-
2019
- 2019-12-04 CY CY20191101278T patent/CY1122416T1/el unknown
-
2020
- 2020-01-16 HR HRP20200067TT patent/HRP20200067T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2240431T3 (en) | 2017-04-10 |
| EP3173400A1 (de) | 2017-05-31 |
| CN104447360B (zh) | 2017-04-12 |
| CN101939287A (zh) | 2011-01-05 |
| EP3173400B1 (de) | 2019-11-06 |
| CY1118976T1 (el) | 2018-01-10 |
| HUE031126T2 (en) | 2017-07-28 |
| HRP20170481T1 (hr) | 2017-05-19 |
| PL2240431T3 (pl) | 2017-07-31 |
| CN104447360A (zh) | 2015-03-25 |
| EP2240431B1 (de) | 2017-01-25 |
| IL206197A0 (en) | 2010-12-30 |
| HUE047275T2 (hu) | 2020-04-28 |
| ES2764451T3 (es) | 2020-06-03 |
| LT2240431T (lt) | 2017-04-10 |
| SI3173400T1 (sl) | 2020-01-31 |
| EP2240431A1 (de) | 2010-10-20 |
| WO2009071310A1 (de) | 2009-06-11 |
| IL237478A0 (en) | 2015-04-30 |
| CN104447361A (zh) | 2015-03-25 |
| CY1122416T1 (el) | 2021-01-27 |
| PT3173400T (pt) | 2019-12-13 |
| CN104447361B (zh) | 2017-04-12 |
| ES2623413T3 (es) | 2017-07-11 |
| US20090149534A1 (en) | 2009-06-11 |
| CN101939287B (zh) | 2014-10-22 |
| IL206197A (en) | 2015-03-31 |
| SI2240431T1 (sl) | 2017-05-31 |
| HRP20200067T1 (hr) | 2020-04-03 |
| US8134032B2 (en) | 2012-03-13 |
| DK3173400T3 (da) | 2019-11-25 |
| PT2240431T (pt) | 2017-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL255201B (en) | Process for preparing (r2, 1r)-3-3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
| PT3173400T (pt) | Modificações cristalinas de (1r, 2r)-3-(3-dimetilamino-1- etil-2-metil-propil)-fenol | |
| IL180373A0 (en) | Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | |
| DK1786403T3 (da) | Mod misbrug sikret, oral indgivelsesform indeholdende (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol | |
| PL1786403T3 (pl) | Doustna postać dawki zabezpieczona przed nadużywaniem zawierająca (1R, 2R)-3-(3-dimetyloamino-1-etylo0-2-metylo-propylo)fenol | |
| SI2086940T1 (sl) | Sol fumarata (alfa s, beta r)-6-bromo-alfa-(2-(dimetilamino)etil)-2-metoksi-alfa-1-naftalenil-beta- fenil-3-kinolinetanola |